D J Gallagher1, J A Konner2, K M Bell-McGuinn2, J Bhatia3, P Sabbatini2, C A Aghajanian2, K Offit3, R R Barakat4, D R Spriggs2, N D Kauff5. 1. Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine; Clinical Genetics Service, Division of Solid Tumor Oncology, Department of Medicine. 2. Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine. 3. Clinical Genetics Service, Division of Solid Tumor Oncology, Department of Medicine. 4. Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA. 5. Clinical Genetics Service, Division of Solid Tumor Oncology, Department of Medicine; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA. Electronic address: kauffn@mskcc.org.
Abstract
BACKGROUND: Patients with BRCA-associated ovarian cancer (OC) have a survival advantage over those with sporadic OC. To further explore this, we examined the impact of prognostic factors on disease-free survival (DFS) and overall survival (OS) in patients with known BRCA mutation status. PATIENTS AND METHODS: We reviewed stage III-IV OC patients treated at our institution between 1 December 1996 and 30 September 2006 and also tested on protocol for BRCA mutations. Impact on DFS and OS was determined by Kaplan-Meier analysis and a Cox proportional hazards model. RESULTS: Of the 110 patients, 36 had deleterious BRCA mutations [BRCA (+)] and 74 were BRCA wild type [BRCA(-)]. Thirty-one of 36 (86%) BRCA (+) and 60 of 74 (81%) BRCA (-) patients were platinum sensitive (P = 0.60). Median OS was longer for BRCA (+) patients (not reached versus 67.8 months; P = 0.02), but DFS was similar (26.9 versus 24.0, P = 0.3). On multivariate analysis, OS correlated with primary platinum sensitivity [HR = 0.15; 95% CI (confidence interval) 0.06-0.34] and BRCA (+) mutation status (HR = 0.33; 95% CI 0.12-0.86). CONCLUSIONS: BRCA mutation status predicted OS independent of primary platinum sensitivity, suggesting that underlying tumor biology contributes to disease outcome and may be worthy of consideration in future clinical trial design.
BACKGROUND:Patients with BRCA-associated ovarian cancer (OC) have a survival advantage over those with sporadic OC. To further explore this, we examined the impact of prognostic factors on disease-free survival (DFS) and overall survival (OS) in patients with known BRCA mutation status. PATIENTS AND METHODS: We reviewed stage III-IV OC patients treated at our institution between 1 December 1996 and 30 September 2006 and also tested on protocol for BRCA mutations. Impact on DFS and OS was determined by Kaplan-Meier analysis and a Cox proportional hazards model. RESULTS: Of the 110 patients, 36 had deleterious BRCA mutations [BRCA (+)] and 74 were BRCA wild type [BRCA(-)]. Thirty-one of 36 (86%) BRCA (+) and 60 of 74 (81%) BRCA (-) patients were platinum sensitive (P = 0.60). Median OS was longer for BRCA (+) patients (not reached versus 67.8 months; P = 0.02), but DFS was similar (26.9 versus 24.0, P = 0.3). On multivariate analysis, OS correlated with primary platinum sensitivity [HR = 0.15; 95% CI (confidence interval) 0.06-0.34] and BRCA (+) mutation status (HR = 0.33; 95% CI 0.12-0.86). CONCLUSIONS:BRCA mutation status predicted OS independent of primary platinum sensitivity, suggesting that underlying tumor biology contributes to disease outcome and may be worthy of consideration in future clinical trial design.
Authors: Alex B Blair; Vincent P Groot; Georgios Gemenetzis; Jishu Wei; John L Cameron; Matthew J Weiss; Michael Goggins; Christopher L Wolfgang; Jun Yu; Jin He Journal: J Am Coll Surg Date: 2018-01-05 Impact factor: 6.113
Authors: David M Hyman; Qin Zhou; Angela G Arnold; Rachel N Grisham; Alexia Iasonos; Noah D Kauff; David Spriggs Journal: Gynecol Oncol Date: 2011-08-19 Impact factor: 5.482
Authors: Stephanie Nougaret; Yulia Lakhman; Mithat Gönen; Debra A Goldman; Maura Miccò; Melvin D'Anastasi; Sarah A Johnson; Krishna Juluru; Angela G Arnold; Ramon E Sosa; Robert A Soslow; Hebert Alberto Vargas; Hedvig Hricak; Noah D Kauff; Evis Sala Journal: Radiology Date: 2017-06-16 Impact factor: 11.105
Authors: Lauren L Ritterhouse; Jonathan A Nowak; Kyle C Strickland; Elizabeth P Garcia; Yonghui Jia; Neal I Lindeman; Laura E Macconaill; Panagiotis A Konstantinopoulos; Ursula A Matulonis; Joyce Liu; Ross S Berkowitz; Marisa R Nucci; Christopher P Crum; Lynette M Sholl; Brooke E Howitt Journal: Mod Pathol Date: 2016-05-06 Impact factor: 7.842
Authors: David M Hyman; Qin Zhou; Alexia Iasonos; Rachel N Grisham; Angela G Arnold; Mary F Phillips; Jasmine Bhatia; Douglas A Levine; Carol Aghajanian; Kenneth Offit; Richard R Barakat; David R Spriggs; Noah D Kauff Journal: Cancer Date: 2011-12-02 Impact factor: 6.860
Authors: Mariam M AlHilli; Marc A Becker; S John Weroha; Karen S Flatten; Rachel M Hurley; Maria I Harrell; Ann L Oberg; Matt J Maurer; Kieran M Hawthorne; Xiaonan Hou; Sean C Harrington; Sarah McKinstry; X Wei Meng; Keith M Wilcoxen; Kimberly R Kalli; Elizabeth M Swisher; Scott H Kaufmann; Paul Haluska Journal: Gynecol Oncol Date: 2016-09-08 Impact factor: 5.482
Authors: J L Meisel; D M Hyman; K Garg; Q Zhou; F Dao; M Bisogna; J Gao; N D Schultz; R N Grisham; M Phillips; A Iasonos; N D Kauff; D A Levine; R A Soslow; D R Spriggs Journal: Ann Oncol Date: 2014-10-03 Impact factor: 32.976